BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Harold Shlevin Joins NeurOp Corporation Board of Directors


11/16/2010 1:16:01 PM

ATLANTA, November 16, 2010 - NeurOp Corporation today announced that Harold Shlevin, Ph.D., has joined its board of directors. Shlevin is a bioscience-industry executive with more than 30 years’ experience in medical devices, pharmaceuticals, diagnostics and vaccines. He currently leads Georgia Tech’s Advanced Technology Development Center (ATDC) as general manager of bioscience commercialization efforts. Shlevin also serves on the boards of Cardiome Pharma Corporation, Georgia Bio and several non-profit organizations.

“Harold has a particularly strong background in business development, strategic planning and licensing,” said James McNamara, M.D., NeurOp’s chairman. “He brings additional depth to our board as NeurOp prepares to advance its first drug candidate into clinical trials for depression and expand its drug discovery program for ischemia.”

“Developing and marketing treatments for central nervous system diseases has long been an area of keen interest for me,” commented Shlevin. “I am privileged to join the NeurOp board and look forward to applying my years of R&D and management experience to help direct their corporate growth and development of new medicines.”

At ATDC, Shlevin is responsible for evaluating and guiding new and emerging bioscience enterprises. His past industry experience includes CEO of Solvay Pharmaceuticals, Inc. and leadership roles at G.D. Searle and Co., Ciba-Geigy Corporation and Altea Therapeutics; he was also a founder of Ciba Vision Ophthalmics and Tikvah Therapeutics. He earned a bachelor’s degree from Boston University and a master’s and doctorate in physiology from the University of Rochester Medical School. He holds a post-doctoral certificate in pharmacology and physiology from the Mayo Graduate School of Medicine where he was an assistant professor.

About NeurOp

NeurOp, Inc., based in Atlanta, Georgia, is a biopharmaceutical company developing innovative medicines for central nervous system disorders including depression, neuropathic pain and ischemia. Its most advanced compounds modulate a well-validated target, the NMDA receptor, in a manner designed to enhance therapeutic benefit while alleviating side effects associated with previous generations of this drug class. A research collaboration with Bristol-Myers Squibb Company (NYSE: BMY) currently funds and supports the development of NeurOp’s proprietary small molecules for the treatment of depression and neuropathic pain. For more information, please visit www.neuropinc.com.

NeurOp Contact:

Barney Koszalka, CEO Phone: 404.941.2350



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES